EMBX Embrex

RESEARCH TRIANGLE PARK, N.C., Jan. 13 /PRNewswire-FirstCall/ -- Embrex, Inc., The In Ovo Company(R), (NASDAQ:EMBX) today announced Andrea Sinclair, D.V.M., was named Field Veterinarian for the United States and Canada. Effectively immediately, she will report to Ron Bryant, Vice President of North American and Latin American sales and service operations. Dr. Sinclair received both her doctorate in veterinary medicine and her Bachelor of Science degree in Poultry Science from North Carolina State University. She received a Master's of Avian Medicine from the University of Georgia College of Veterinary Medicine, Poultry Diagnostic and Research Center. She has developed and implemented several projects involving competitive exclusion products, Mycoplasma iowae, and reovirus. She has also participated in various aspects of poultry health management and research administration. "Embrex's reputation for providing high-value technical and customer service is second to none. We seek to continuously improve the service level we provide to our customer and believe Dr. Sinclair's background offers a broad range of experience that will prove extremely useful to our customers," said Bryant. About Embrex Celebrating its 20th anniversary, Embrex, Inc., The In Ovo Company(R), headquartered in Research Triangle Park, NC, is an international biotechnology company engaged in the development of innovative in ovo (in the egg) solutions that meet the needs of today's global poultry industry. The company's unique integration of several scientific and engineering disciplines enables it to be the leading provider of in ovo, value-added solutions with its automated injection and detection devices as well as its select vaccines. For additional information, visit the company web site at http://www.embrex.com/. Embrex(R), Inovoject(R), Inovocox(TM), and The In Ovo Company(R) are trademarks of Embrex, Inc. FORWARD LOOKING STATEMENT FOLLOWS This release contains forward-looking statements, including statements with respect to future financial results, products, services, and markets. These statements involve risks and uncertainties that could cause actual results to differ materially. Risks include without limitation the degree of growth in the poultry industry in the United States and globally, competition arising in the United States and elsewhere, possible decreases in production by our customers, avian disease outbreaks in Embrex's markets, market acceptance and cost of expansion in new geographic markets and with new products, including the Company's ability to penetrate new markets and the degree of market acceptance of new products, the ability of Embrex's contract manufacturers to support our products, the complete commercial development of potential future products on a cost effective basis, including Inovocox(TM), and the ability to obtain regulatory approval of products. Such approval is dependent upon a number of factors, such as results of trials, the discretion of regulatory officials, and potential changes in regulations. Additional information on these risks and other factors, which could affect the Company's financial results, is included in the Company's Forms 10-K, 10-Q and other filings with the Securities and Exchange Commission. CONTACT: Ellen Corliss Vice President, Investor Relations & Corporate Communications (919) 314-2561 DATASOURCE: Embrex, Inc. CONTACT: Ellen Corliss, Vice President, Investor Relations & Corporate Communications of Embrex, Inc., +1-919-314-2561 Web site: http://www.embrex.com/

Copyright